Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.60 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | HCK | P08631 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | SIK1 | P57059 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.50 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517484 | 0.88 | AURKA (0.63) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6524095 | 0.87 | AURKA (0.61) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6519116 | 0.85 | AURKA (0.63) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6521119 | 0.83 | AURKA (0.60) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6521527 | 0.82 | AURKA (0.82) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6522191 | 0.81 | PTK6 (0.77) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6516169 | 0.76 | PTK6 (0.57) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6519719 | 0.76 | AURKA (0.59) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL6519736 | 0.76 | AURKA (0.57) | AURKAPTK6AURKBERBB2MAPK13 | |
| SCHEMBL3454240 | 0.75 | AURKA (1.00) | AURKAAURKBERBB2MAPK13CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | AURKA 538/4885PTK6 186/4885AURKB 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.